12/26/2025
Ten years ago, Norman resident Mike Schuster was diagnosed with glioblastoma, a deadly brain cancer with a survival rate of just 12–14 months. After surgeries failed, he joined an OU Health Stephenson Cancer Center Phase I clinical trial for OKN-007, an experimental drug developed at OMRF.
Less toxic and more targeted than traditional chemotherapy, the treatment likely boosted his survival. Stephenson Cancer Center neuro-oncologist Dr. James Battiste describes Mike as a leading figure in treatment and survivorship. His story highlights the impact of research and clinical trials on improving outcomes for aggressive cancers. Stephenson Cancer Center offers the state's only dedicated Phase I program, providing "first-in-human" access to new drugs and ranking among the nation's top programs.
You can see more of Mike's story on KWTV - NEWS 9's website here: https://brnw.ch/21wYEcV